BioPharma Dive - Latest News

GSK targets neurodegenerative diseases with latest licensing deal

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

Apr 7, 2025 - 17:10
 0
GSK targets neurodegenerative diseases with latest licensing deal

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

Read More

Tags:

Previous Article

Not the Tasman: Kia Working On a New Truck Model for U.S. Buyers

Next Article

Spring 2025 Wedding Trends Are Here, Courtesy of Lulus' Debut Report

Related Posts

Arbor raises $74M amid genetic medicine’s funding slump

Arbor raises $74M amid genetic medicine’s funding slump

Mar 18, 2025  0

Cargo shelves cell therapy research, lays off more staff

Cargo shelves cell therapy research, lays off more staff

Mar 19, 2025  0

Pfizer stops selling hemophilia gene therapy, citing weak demand

Pfizer stops selling hemophilia gene therapy, citing we...

Feb 21, 2025  0